This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): MDX-010, anti-CTLA-4, BMS-734016, ipilimumab
Description: MDX-010 is a fully human antibody that targets an immune receptor known as CTLA-4. This receptor, which is a protein found on the surface of T-cells, normally functions to suppress the immune response to tumors or infectious agents.
Bristol-Myers Squibb and Medarex
Bristol-Myers Squibb Company and Medarex announced on 1/13/05 that the global development and commercialization collaboration agreement, previously announced by both companies on 11/8/04, had become effective.
Under the collaboration agreement, Bristol-Myers Squibb and Medarex plan to jointly develop MDX-010, a fully human antibody investigational product targeting the CTLA-4 receptor.
Medarex will receive an initial cash payment of $50 million, of which $25 million will be for a purchase of Medarex's common stock by Bristol-Myers Squibb. In addition, Medarex could receive up to $205 million if all regulatory milestones are met, and up to $275 million in sales- related milestones. Medarex has an option to co-promote and share profits with Bristol-Myers Squibb in the United States. Bristol-Myers Squibb will receive an exclusive license outside of the United States and will pay royalties to Medarex on any commercial sales.
In July...See full deal structure in Biomedtracker
Partners: Ono Pharmaceutical Company, Ltd.
Additional information available to subscribers only: